DK1456238T3 - Produktion af F(ab')2-fragmenter i pattedyrceller - Google Patents

Produktion af F(ab')2-fragmenter i pattedyrceller

Info

Publication number
DK1456238T3
DK1456238T3 DK02789019T DK02789019T DK1456238T3 DK 1456238 T3 DK1456238 T3 DK 1456238T3 DK 02789019 T DK02789019 T DK 02789019T DK 02789019 T DK02789019 T DK 02789019T DK 1456238 T3 DK1456238 T3 DK 1456238T3
Authority
DK
Denmark
Prior art keywords
fragments
production
mammalian cells
antibody fragments
bivalent
Prior art date
Application number
DK02789019T
Other languages
English (en)
Inventor
Abraham Bout
David Halford Ashton Jones
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of DK1456238T3 publication Critical patent/DK1456238T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624Disulfide-stabilized antibody (dsFv)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/108Plasmid DNA episomal vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK02789019T 2001-12-17 2002-12-17 Produktion af F(ab')2-fragmenter i pattedyrceller DK1456238T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL0100917 2001-12-17
PCT/NL2002/000841 WO2003051927A2 (en) 2001-12-17 2002-12-17 Production of f(ab')2 fragments in mammalian cells

Publications (1)

Publication Number Publication Date
DK1456238T3 true DK1456238T3 (da) 2008-08-18

Family

ID=19760784

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02789019T DK1456238T3 (da) 2001-12-17 2002-12-17 Produktion af F(ab')2-fragmenter i pattedyrceller

Country Status (11)

Country Link
US (2) US20050048038A1 (da)
EP (1) EP1456238B1 (da)
AT (1) ATE397019T1 (da)
AU (1) AU2002353662B2 (da)
CA (1) CA2470579C (da)
DE (1) DE60226896D1 (da)
DK (1) DK1456238T3 (da)
ES (1) ES2307807T3 (da)
NZ (1) NZ533332A (da)
SI (1) SI1456238T1 (da)
WO (1) WO2003051927A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
KR100979025B1 (ko) 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
WO2003051927A2 (en) 2001-12-17 2003-06-26 Crucell Holland B.V. Production of f(ab')2 fragments in mammalian cells
CN100383238C (zh) 2003-05-09 2008-04-23 克鲁塞尔荷兰公司 E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法
WO2019070108A1 (es) 2017-10-02 2019-04-11 Laboratorios Silanes S.A. De C.V. Proceso de alto rendimiento para la producción de antivenenos de fragmentos f (ab') 2 de anticuerpos
WO2023205656A2 (en) * 2022-04-18 2023-10-26 John Paul Ii Medical Research Institute Immortalized cells for production of bioproducts, methods of producing bioproducts with an immortalized cell, and methods of making immortalized cells for production of bioproducts

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
EP0173552B1 (en) * 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1993006217A1 (en) * 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
SI0833934T2 (sl) * 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
CN100457914C (zh) * 1999-04-15 2009-02-04 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
EP1130099A1 (en) * 2000-02-25 2001-09-05 Crucell Holland B.V. Activated vitronectin as a marker of angiogenesis detected with phage antibodies
WO2003051927A2 (en) 2001-12-17 2003-06-26 Crucell Holland B.V. Production of f(ab')2 fragments in mammalian cells

Also Published As

Publication number Publication date
CA2470579C (en) 2012-03-06
SI1456238T1 (sl) 2008-08-31
US7537916B2 (en) 2009-05-26
DE60226896D1 (de) 2008-07-10
WO2003051927A2 (en) 2003-06-26
US20050048038A1 (en) 2005-03-03
NZ533332A (en) 2005-07-29
WO2003051927A3 (en) 2003-11-20
US20080166767A1 (en) 2008-07-10
EP1456238B1 (en) 2008-05-28
AU2002353662A1 (en) 2003-06-30
ES2307807T3 (es) 2008-12-01
CA2470579A1 (en) 2003-06-26
AU2002353662B2 (en) 2009-04-23
ATE397019T1 (de) 2008-06-15
EP1456238A2 (en) 2004-09-15

Similar Documents

Publication Publication Date Title
EP1362093A4 (en) QUICK PRODUCTION OF MONOCLONAL ANTIBODIES
DK1379671T3 (da) Fremgangsmåder til dyrkning af circovirus
DK1456238T3 (da) Produktion af F(ab')2-fragmenter i pattedyrceller
IL162648A0 (en) Cellular compositions and methods of making and using them
DK1650307T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner ved anvendelse af apoptoseinhibitorer
AU2002364935A1 (en) Enhancement of immune responses by 4-1bb-binding agents
FR15C0055I1 (da)
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
DK0918848T3 (da) Fremgangsmåder til at behandle kræftsygdomme og patogene infektioner ved anvendelse af antigenpræsenterende celler påfyldt med RNA
DE60037450D1 (de) Funf-helix protein
HUP0105052A2 (hu) Eljárások nukleinsav amplifikálására és szekvenálására
BR0015224A (pt) Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado
TR200300478T2 (tr) Hümanize antiLT-ß-R antikorları
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
ES2150573T3 (es) Composicion que contiene autoanticuerpos para la terapia y profilaxis tumorales.
NZ592159A (en) Means and methods for influencing the stability of antibody producing cells
CA2437962A1 (en) Method of extracting virus from cell culture
EP0763057A4 (en) METHOD OF MULTIPLICATION AND DIFFERENTIATION OF B CELLS AND THEIR USE
PT1200561E (pt) Clone celular recombinante estavel, sua producao e utilizacao
BR0100982A (pt) Processo para a preparação de derivados deresorcinol
NO20061470L (no) Fremgangsmate for fremstilling av gamma-karboksylerte proteiner
MXPA03008882A (es) Composiciones y metodos utiles para la infeccion por hcv.
PL367306A1 (pl) Szczepionki na bazie autologicznych komórek T i sposoby ich otrzymywania
FR2833610B1 (fr) Construits cellulaires cultives in vitro, preparation et utilisations
GB2351296A (en) Keratinocyte stem cells